• A+ Standard
  • A+ Larger
  • A+ Extra Large

  • Standard Contrast
  • Low Contrast
  • High Contrast

A Phase 1 Open-Label, Dose-Escalation Study of Central Nervous System-Penetrant Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PRT3645, in Patients With Select Advanced or Metastatic Solid Tumors

Manish R. Patel, Atrayee Basu-Mallick, Filemon Dela Cruz, Douglas Orr, Alex Spira, Guru P. Sonpavde, Pooja Ghatalia, Christine Lihou, Neelesh Sharma, Peggy Scherle, Jennifer Xavier, William Sun, Sri Sahasranaman, Jason T. Henry

Poster presented at the

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023, October 11-15, 2023, Boston, MA, USA

This is an electronic reproduction of a poster presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023, October 11-15, 2023, Boston, MA, USA. All copyrights remain those of the copyright holder. This page will not be available after November 14, 2023.